Related references
Note: Only part of the references are listed.Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome
Evanthia Diamanti-Kandarakis et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome
Ramin Alemzadeh et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Ovulation Induction in Polycystic Ovary Syndrome No. 242, May 2010
Tannys D. R. Vause et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2010)
Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society
Robert A. Wild et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus
Hiroyuki Ito et al.
NUTRITION & METABOLISM (2010)
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Thomas Tang et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2010)
Effectiveness of long-term (twelve months) nonsurgical weight loss interventions for obese women with polycystic ovary syndrome: a systematic review
Fiona Nicholson et al.
INTERNATIONAL JOURNAL OF WOMENS HEALTH (2010)
Determinants of Interleukin-6 and C-Reactive Protein Vary in Polycystic Ovary Syndrome, as Do Effects of Short- and Long-Term Metformin Therapy
Tasoula Tsilchorozidou et al.
HORMONE RESEARCH (2009)
Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial
Soren S. Lund et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment
Dennis Heutling et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Impact of obesity on the risk for polycystic ovary syndrome
Bulent O. Yildiz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Use of metformin in polycystic ovary syndrome - A meta-analysis
Andreea A. Creanga et al.
OBSTETRICS AND GYNECOLOGY (2008)
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial
S. S. Lund et al.
DIABETES OBESITY & METABOLISM (2007)
Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma?
C. Belosi et al.
HUMAN REPRODUCTION (2006)
Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS
H. J. Teede et al.
ENDOCRINE (2006)
Cardiovascular risk in women with polycystic ovary syndrome
Francesco Orio et al.
FERTILITY AND STERILITY (2006)
Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin
Evanthia Diamanti-Kandarakis et al.
HUMAN REPRODUCTION (2006)
The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes
LA Donnelly et al.
DIABETIC MEDICINE (2006)
Central fat excess in polycystic ovary syndrome:: Relation to low-grade inflammation and insulin resistance
JJ Puder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Medical progress: Polycystic ovary syndrome
DA Ehrmann
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome
F Orio et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)
BCJM Fauser et al.
HUMAN REPRODUCTION (2004)
Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease
N Boulman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
JM Lord et al.
BRITISH MEDICAL JOURNAL (2003)
Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome
L Morin-Papunen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet
PG Crosignani et al.
HUMAN REPRODUCTION (2003)
Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome
RC Christian et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
PM Ridker
CIRCULATION (2003)
A pilot study of the long-term effects of acipimox in polycystic ovarian syndrome
M Ciampelli et al.
HUMAN REPRODUCTION (2002)
Low grade chronic inflammation in women with polycystic ovarian syndrome
CCJ Kelly et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
High-sensitivity C-reactive protein - Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
PM Ridker
CIRCULATION (2001)
Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome
R Pasquali et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans
A Katz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
P Moghetti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: A randomized study
LC Morin-Papunen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)